
Opinion|Videos|August 5, 2024
Improving Insurance Coverage for RSV Vaccines
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
- How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
- How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
Advertisement
Related to this article

Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.

Rural patients with HFrEF had lower mortality when treated at urban hospitals but higher early mortality than urban patients at those hospitals.

Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Menopause Benefit Design Should Prioritize Access, Total Cost of Care
5


